Weeks 1–48 and during the entire treatment period
Clinical benefit as assessed with the response indicators RBC-TI for ≥ 8 weeks, ≥ 50% reduction in transfusion burden, and HI-E response is shown in Fig. Response indicators across analysis periods. Evaluated in patients who did not achieve RBC-TI for ≥ 8 weeks by week 25 but continued luspatercept treatment (